|
AU2007317347B2
(en)
*
|
2006-11-03 |
2014-02-06 |
Alphavax, Inc. |
Alphavirus and alphavirus replicon particle formulations and methods
|
|
US20090111099A1
(en)
*
|
2007-10-27 |
2009-04-30 |
Yongsheng Ma |
Promoter Detection and Analysis
|
|
US8067241B2
(en)
*
|
2009-08-26 |
2011-11-29 |
General Electric Company |
Method and apparatus for antigen retrieval process
|
|
ES2680915T3
(es)
*
|
2010-01-28 |
2018-09-11 |
The Children's Hospital Of Philadelphia |
Plataforma de fabricación escalable para la purificación de vectores virales y vectores virales purificados de este modo para su utilización en terapia génica
|
|
KR101549296B1
(ko)
|
2010-04-14 |
2015-09-01 |
이엠디 밀리포어 코포레이션 |
고역가 고순도 바이러스 스톡의 생산 방법 및 이의 사용 방법
|
|
WO2012018628A1
(en)
|
2010-07-26 |
2012-02-09 |
Board Of Regents, The University Of Texas System |
Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
|
|
EP2686423A4
(en)
*
|
2011-03-14 |
2015-01-28 |
Nat Res Council Canada |
METHOD FOR PRODUCING VIRUSES IN CELLS
|
|
CA2856137A1
(en)
|
2011-11-22 |
2013-05-30 |
The Children's Hospital Of Philadelphia |
Virus vectors for highly efficient transgene delivery
|
|
EP2790737B1
(en)
*
|
2011-12-12 |
2018-11-21 |
The Children's Hospital of Philadelphia |
Large commercial scale lentiviral vector production system and vectors produced thereby
|
|
US9974850B2
(en)
|
2013-01-25 |
2018-05-22 |
Board Of Regents, The University Of Texas System |
Immunogenic compositions and uses thereof
|
|
KR102219672B1
(ko)
*
|
2013-06-17 |
2021-02-25 |
드 슈타트 데르 네덜란덴, 베르테겐부어디그트 두어 드 미니스터 반 베이웨이에스, 미니스테리 반 폭스겐트존하이트, 벨지인 엔 스포츠 |
바이러스 성분의 어그리게이션을 저해하는 방법
|
|
US10161011B2
(en)
|
2013-11-29 |
2018-12-25 |
Takara Bio Inc. |
Method for quantifying adeno-associated virus
|
|
CN114395559A
(zh)
|
2014-04-25 |
2022-04-26 |
吉尼松公司 |
高胆红素血症的治疗
|
|
EP3151866B1
(en)
|
2014-06-09 |
2023-03-08 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
US10526583B2
(en)
|
2014-07-02 |
2020-01-07 |
University Of Florida Research Foundation, Incorporated |
Compositions and methods for purifying recombinant adeno-associated virus
|
|
JP6401871B2
(ja)
|
2014-11-05 |
2018-10-10 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
パーキンソン病の治療のためのａａｄｃポリヌクレオチド
|
|
US10570395B2
(en)
|
2014-11-14 |
2020-02-25 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
RU2716422C2
(ru)
|
2014-11-14 |
2020-03-11 |
Вояджер Терапьютикс, Инк. |
Композиции и способы лечения бокового амиотрофического склероза (als)
|
|
HK1245326A1
(zh)
|
2014-12-12 |
2018-08-24 |
Voyager Therapeutics, Inc. |
用於生产scaav的组合物和方法
|
|
CN107428799A
(zh)
|
2015-01-13 |
2017-12-01 |
阿尔法韦士曼公司 |
纯化腺相关病毒(AAV)及/或重组腺相关病毒(rAAV)之方法及其梯度和流通式缓冲液
|
|
EP3054007A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
|
|
EP3368054A4
(en)
|
2015-10-28 |
2019-07-03 |
Voyager Therapeutics, Inc. |
REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
|
|
WO2017087395A1
(en)
|
2015-11-16 |
2017-05-26 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for treatment of titin-based myopathies and other titinopaties
|
|
US11015174B2
(en)
*
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV8
|
|
ES2938833T3
(es)
|
2016-03-28 |
2023-04-17 |
Ultragenyx Pharmaceutical Inc |
Métodos de inactivación térmica de adenovirus
|
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
SG11201809643UA
(en)
|
2016-05-18 |
2018-12-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
US10584337B2
(en)
|
2016-05-18 |
2020-03-10 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
IL301963A
(en)
*
|
2016-07-21 |
2023-06-01 |
Spark Therapeutics Inc |
Scalable High Recovery Methods for High-Throughput Recombinant Adeno-Associated Viral Vector Production and Recombinant Adeno-Associated Viral Vectors Made So
|
|
WO2018039375A1
(en)
|
2016-08-23 |
2018-03-01 |
Akouos, Inc. |
Compositions and methods for treating non-age-associated hearing impairment in a human subject
|
|
EP3831281A1
(en)
|
2016-08-30 |
2021-06-09 |
The Regents of The University of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
EP3293260A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
IL299325B2
(en)
|
2016-09-12 |
2025-08-01 |
Inst Nat Sante Rech Med |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3293203A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3293259A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
WO2018050872A1
(en)
|
2016-09-16 |
2018-03-22 |
Leukocare Ag |
A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
|
|
BR112019009113A2
(pt)
*
|
2016-11-04 |
2019-07-16 |
Baxalta GmbH |
formulações de vírus adenoassociado
|
|
US10626376B2
(en)
|
2016-11-14 |
2020-04-21 |
St. Jude Children's Research Hospital |
Method for isolating and purifying adeno-associated virus particles using salt
|
|
US10294452B2
(en)
*
|
2016-11-22 |
2019-05-21 |
Dao-Yao He |
Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
|
|
US11357735B2
(en)
|
2017-02-01 |
2022-06-14 |
Centre National De La Recherche Scientifique |
Particles and compositions comprising the same for transfection
|
|
US11541131B2
(en)
|
2017-03-10 |
2023-01-03 |
Genethon |
Treatment of glycogen storage disease III
|
|
EP3619308A4
(en)
|
2017-05-05 |
2021-01-27 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT FOR HUNTINGTON'S MORBUS
|
|
CN110913866A
(zh)
|
2017-05-05 |
2020-03-24 |
沃雅戈治疗公司 |
治疗肌萎缩性侧索硬化(als)的组合物和方法
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
WO2019018342A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
NETWORK EQUIPMENT TRACK GUIDE SYSTEM
|
|
CA3071978A1
(en)
|
2017-08-03 |
2019-02-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
EP3687582A4
(en)
|
2017-09-29 |
2021-07-14 |
Voyager Therapeutics, Inc. |
RESCUE OF CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE OF FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
|
|
EP4454654A3
(en)
|
2017-10-16 |
2025-02-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
US11434502B2
(en)
|
2017-10-16 |
2022-09-06 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (ALS)
|
|
CN120501895A
(zh)
|
2017-11-08 |
2025-08-19 |
诺华股份有限公司 |
制备病毒载体的手段和方法及其用途
|
|
CA3084802A1
(en)
*
|
2017-12-05 |
2019-06-13 |
Applied Genetic Technologies Corporation |
Formulation optimization for viral particles
|
|
CA3089080A1
(en)
|
2018-01-31 |
2019-08-08 |
Research Institute At Nationwide Children's Hospital |
Gene therapy for limb-girdle muscular dystrophy type 2c
|
|
JP7467356B2
(ja)
|
2018-02-07 |
2024-04-15 |
ジェネトン |
ハイブリッド調節要素
|
|
WO2019173434A1
(en)
|
2018-03-06 |
2019-09-12 |
Voyager Therapeutics, Inc. |
Insect cell manufactured partial self-complementary aav genomes
|
|
CA3097192A1
(en)
|
2018-04-27 |
2019-10-31 |
Voyager Therapeutics, Inc. |
Methods for measuring the potency of aadc viral vectors
|
|
US12319929B2
(en)
|
2018-05-15 |
2025-06-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of Parkinson's disease
|
|
WO2019222441A1
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
|
US20210214749A1
(en)
|
2018-05-16 |
2021-07-15 |
Voyager Therapeutics, Inc. |
Directed evolution
|
|
EP3801638A1
(en)
|
2018-06-08 |
2021-04-14 |
Novartis AG |
Cell-based assay for measuring drug product potency
|
|
AU2019295779B2
(en)
|
2018-06-29 |
2025-04-24 |
Research Institute At Nationwide Children's Hospital |
Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2A
|
|
SG11202012044QA
(en)
|
2018-06-29 |
2021-01-28 |
Wuhan Neurophth Biological Tech Limited Company |
Compositions and methods for treating leber's hereditary optic neuropathy
|
|
US20210254103A1
(en)
|
2018-07-02 |
2021-08-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
|
AU2019299964A1
(en)
*
|
2018-07-11 |
2021-01-21 |
Takeda Pharmaceutical Company Limited |
AAV compositions
|
|
EP3826719A1
(en)
|
2018-07-24 |
2021-06-02 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
FI3833746T3
(fi)
|
2018-08-08 |
2023-06-01 |
Genethon |
Mini-GDE glykogenoosi III:n hoitamiseksi
|
|
CN112567027A
(zh)
*
|
2018-08-10 |
2021-03-26 |
再生生物股份有限公司 |
用于重组aav生产的可扩展方法
|
|
KR20210068014A
(ko)
|
2018-08-20 |
2021-06-08 |
우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 |
레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
|
|
KR20210068068A
(ko)
|
2018-09-28 |
2021-06-08 |
보이저 테라퓨틱스, 인크. |
조작된 프로모터를 갖는 프라탁신 발현 구축물 및 그의 사용 방법
|
|
US20210348242A1
(en)
|
2018-10-04 |
2021-11-11 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
JP2022522995A
(ja)
|
2019-01-18 |
2022-04-21 |
ボイジャー セラピューティクス インコーポレイテッド |
Ａａｖ粒子を生成するための方法及びシステム
|
|
SG11202109113TA
(en)
|
2019-02-26 |
2021-09-29 |
Res Inst Nationwide Childrens Hospital |
Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy
|
|
KR20210148273A
(ko)
|
2019-04-08 |
2021-12-07 |
제네똥 |
근육 발현을 위한 하이브리드 프로모터
|
|
BR112021020888A2
(pt)
|
2019-04-19 |
2021-12-21 |
Genethon |
Terapia gênica de doenças hipofosfatêmicas relacionadas a fator de crescimento fibroblástico 23
|
|
CN113993552A
(zh)
|
2019-04-19 |
2022-01-28 |
再生生物股份有限公司 |
腺相关病毒载体制剂和方法
|
|
WO2020223274A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
|
AU2020319168B2
(en)
|
2019-07-25 |
2024-02-29 |
Novartis Ag |
Regulatable expression systems
|
|
WO2021030125A1
(en)
|
2019-08-09 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
US20220325250A1
(en)
|
2019-08-14 |
2022-10-13 |
Leukocare Ag |
Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
|
|
US11155835B2
(en)
*
|
2019-08-19 |
2021-10-26 |
The Catholic University Of America |
Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
|
|
US11401530B2
(en)
|
2019-08-19 |
2022-08-02 |
The Catholic University Of America |
Bacteriophage-based artificial viruses for human genome remodeling
|
|
EP4017871B1
(en)
|
2019-08-21 |
2024-01-17 |
Research Institute at Nationwide Children's Hospital |
Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
|
|
US20220364114A1
(en)
|
2019-08-26 |
2022-11-17 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
CA3156984A1
(en)
|
2019-10-07 |
2021-04-15 |
Regenxbio Inc. |
Adeno-associated virus vector pharmaceutical composition and methods
|
|
CA3151442A1
(en)
|
2019-10-22 |
2021-04-29 |
Pasqualina COLELLA |
Sortilin receptor ligand based chimeric polypeptides and uses thereof
|
|
WO2021078834A1
(en)
|
2019-10-22 |
2021-04-29 |
Genethon |
Chimeric acid-alpha glucosidase polypeptides and uses thereof
|
|
CN113025633B
(zh)
|
2019-12-09 |
2024-08-27 |
武汉纽福斯生物科技有限公司 |
编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
|
|
KR102167829B1
(ko)
*
|
2020-02-10 |
2020-10-20 |
주식회사 이노테라피 |
아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법
|
|
IL295747A
(en)
|
2020-02-21 |
2022-10-01 |
Akouos Inc |
Preparations and methods for the treatment of hearing impairment that is not related to age in humans
|
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
|
EP3913060A1
(en)
|
2020-05-22 |
2021-11-24 |
Genethon |
Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
|
|
AU2021284250A1
(en)
*
|
2020-06-02 |
2023-02-09 |
Janssen Biotech, Inc. |
Materials and methods for viral purification
|
|
EP4192514A1
(en)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
IL300323A
(en)
*
|
2020-08-07 |
2023-04-01 |
Janssen Biotech Inc |
Formulations for viral particles with a high degree of purity
|
|
EP4200410A1
(en)
|
2020-08-24 |
2023-06-28 |
Genethon |
C-terminal truncated gde for the treatment of glycogen storage disease iii
|
|
JP7733110B2
(ja)
|
2020-11-02 |
2025-09-02 |
バイオマリン ファーマシューティカル インコーポレイテッド |
アデノ随伴ウイルスを濃縮するためのプロセス
|
|
EP4259790A1
(en)
|
2020-12-09 |
2023-10-18 |
Genethon |
Lysosomal acid lipase variants and uses thereof
|
|
WO2022187548A1
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
EP4301768A2
(en)
|
2021-03-03 |
2024-01-10 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2022236008A1
(en)
*
|
2021-05-07 |
2022-11-10 |
Board Of Regents, The University Of Texas System |
Methods and compositions for transport, storage, and delivery of adeno-associated viral vector and other molecules
|
|
CA3226119A1
(en)
|
2021-08-04 |
2023-02-09 |
Giuseppe RONZITTI |
Hybrid promoters for gene expression in muscles and in the cns
|
|
JP2024534410A
(ja)
|
2021-09-16 |
2024-09-20 |
ノバルティス アーゲー |
新規転写因子
|
|
EP4219726A1
(en)
|
2021-10-15 |
2023-08-02 |
Research Institute at Nationwide Children's Hospital |
Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
|
|
WO2023073526A1
(en)
|
2021-10-25 |
2023-05-04 |
Novartis Ag |
Methods for improving adeno-associated virus (aav) delivery
|
|
EP4511392A1
(en)
|
2022-03-17 |
2025-02-26 |
Innoskel |
Polynucleotides encoding the alpha-1 chain of human type ii collagen and methods of their use
|
|
EP4514839A1
(en)
|
2022-03-17 |
2025-03-05 |
Innoskel |
Hybrid promoters and their use in osteolysis syndrome
|
|
EP4519463A1
(en)
|
2022-05-06 |
2025-03-12 |
Novartis AG |
Novel recombinant aav vp2 fusion polypeptides
|
|
WO2023237731A1
(en)
|
2022-06-09 |
2023-12-14 |
Genethon |
N-terminal truncated gde for the treatment of glycogen storage disease iii
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
TW202426017A
(zh)
*
|
2022-11-24 |
2024-07-01 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
非包膜病毒的藥物組合物
|
|
WO2025003477A1
(en)
|
2023-06-29 |
2025-01-02 |
Genethon |
N-terminal truncated glycogen debranching enzymes for the treatment of glycogen storage disease iii
|
|
EP4606892A1
(en)
|
2024-02-23 |
2025-08-27 |
Merck Patent GmbH |
Methods for the production of viral particles
|